Last update 21 Nov 2024
Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel)
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Cell therapy |
Synonyms- |
Target- |
Mechanism Cell replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel)Phase I Clinical Trial on Intratumoral Administration of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Avelumab and Ipilimumab in Combination With Intravenously Administered Nivolumab
100 Clinical Results associated with Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel)
Login to view more data
100 Translational Medicine associated with Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel)
Login to view more data
100 Patents (Medical) associated with Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel)
Login to view more data
100 Deals associated with Autologous CD1c (BDCA-1)+ myDC(Universitair Ziekenhuis Brussel)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Solid tumor | Phase 1 | BE | 29 Jan 2018 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT03707808 (ESMO2024) Manual  | Phase 1 | 6 | Autologous CD1c(BDCA-1)+/CD141(BDCA-3)+myeloid dendritic cells (myDC) with AS01B plus ipilimumab (IPI) and nivolumab (NIVO) | (nrnvopaued) = Treatment related adverse events (TRAE) included transient grade 1/2 injection site reactions and constitutional symptoms. One pt experienced a grade 3 systemic inflammatory syndrome with a lymphocytic peritoneal exudate (responsive to corticosteroids). There were no grade 4-5 TRAE. zcfyfwnmne (yvaiyeuznd ) | Positive | 14 Sep 2024 | |
NCT03707808 (Pubmed) Manual | Phase 1 | Refractory Melanoma CD1c (BDCA-1) | CD141 (BDCA-3) | 8 | (ikeveqeplo) = zlsxaklnwx wcfiszxnyr (jjkikccjub ) View more | Positive | 11 Jan 2024 | |
NCT03707808 (SITC2022) Manual | Phase 1 | BRAF V600 mutation-positive Melanoma BRAF V600 | 8 | (dcngeqesqr) = gqqbbnpxrf brvgwqivkk (damcuvymhd, 5.193 - 15.007) View more | Positive | 01 Nov 2022 | |
NCT03707808 (ASCO2019) Manual | Phase 1 | HR-positive/HER2-low Solid Tumors Second line | 6 | (soezgowhxj) = transient G 2 local pain at injection site in 2 pts, G1 pruritus in 2 pts, G2 pneumonitis in 1 pt, G1 rash in 1 pt, pruritus and redness of the skin overlaying the injected lesion in 1 pt udjlyjxiyu (cwwrpzbetg ) View more | Positive | 31 May 2019 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free